Infinity Pharmaceuticals Investor Relations Material
Latest events
Investor Update
Infinity Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Infinity Pharmaceuticals Inc
Access all reports
Infinity Pharmaceuticals, Inc. is a biopharmaceutical company which focuses on developing novel medicines for people with cancer. The Company's pipeline includes DVC-1201, an anti-CD20 monoclonal antibody for the treatment of B-cell lymphoma and follicular lymphoma; DVC-1202, an anti-IGF-1R monoclonal antibody for the treatment of colorectal cancer; and is also developing an oral pan-Immunoglobulin product candidate that targets certain cancers
Latest articles
Companies That Had Their IPO in 2023: Cautious Optimism
The cautiously optimistic market in 2023 saw stocks rebounded upwards, and interest in IPOs picked up from the previous year.
15 Apr 2024
Puig's 2024 IPO: Paco Rabanne, Jean Paul Gaultier, and Beyond
Explore Puig's journey from its 1914 inception to a 2024 IPO, showcasing its growth, strategic acquisitions, and impact in the beauty and fashion industry.
15 Apr 2024
Alphabet's Unstoppable Rise: From Stanford to Global Tech Leader
Discover Alphabet's rise from a university project to a global tech leader, highlighting its growth, diversification, and visionary leadership.
15 Apr 2024
Ticker symbol
Country
🇺🇸 United States